Vimarsana
Biggest News Aggregation in the World

Fourth Indication News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fourth Indication. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fourth Indication Today - Breaking & Trending Today

KITE'S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL) - Vimarsana News

KITE'S CAR T-CELL THERAPY TECARTUS® (BREXUCABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (r/r ALL)

Published: September 7, 2022

KITE’S  CAR  T-CELL  THERAPY  TECARTUS®  (BREXUCABTAGENE  AUTOLEUCEL)  GRANTED EUROPEAN MARKETING AUTHORISATION FOR THE TREATMENT OF  RELAPSED  OR  REFRACTORY  ACUTE  LYMPHOBLASTIC  LEUKAEMIA  (r/r ALL) -- Approval Marks Kite’...

Source: pharmiweb.com
Related Topics:
United StatesSanta MonicaUnited KingdomFoster CityChristi ShawBrexucabtagene AutoleucelMaxs ToppGilead SciencesEuropean CommissionUniversity Hospital Of WuerzburgGilead Sciences IncSociety CanadaExchange CommissionGilead CompanyEuropean Medicines AgencyMarks KiteFourth IndicationTwo Cell TherapiesComplete RemissionMedian Overall SurvivalMore Than Two YearsAll PatientsAlmost Four YearsResponders DemonstratedUniversity Hospital
Gilead Sciences, Inc.: Kite's CAR T-cell Therapy Tecartus Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) - Vimarsana News

Gilead Sciences, Inc.: Kite's CAR T-cell Therapy Tecartus Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)

Published: September 6, 2022

-- Approval Marks Kite's Fourth Indication in Europe for its Two Cell Therapies and First in Leukemia -- -- Overall Complete Remission of 71% and a Median Overall Survival of More Than Two Years

Source: finanznachrichten.de
Related Topics:
United StatesSanta MonicaFoster CityChristi ShawJacquie RossMaxs ToppAnna PadulaGilead SciencesEuropean CommissionUniversity Hospital Of WuerzburgGilead Sciences IncExchange CommissionGilead CompanyGilead Company NasdaqMarks KiteFourth IndicationTwo Cell TherapiesComplete RemissionMedian Overall SurvivalMore Than Two YearsAll PatientsAlmost Four YearsResponders DemonstratedUniversity HospitalRelease Syndrome
U.S. FDA Approves Kite's Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Vimarsana News

U.S. FDA Approves Kite's Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Published: October 2, 2021

65% of Patients Achieved Overall Complete Remission with Tecartus -- -- High Unmet Need: Fifty Percent of Adult Patients Will Relapse on Currently Available Treatments -- -- Approval Marks Kite’s Fourth Indication for its Cell Therapies and First in Leukemia -- Kite, a Gilead Company today announced the U.S. Food and Drug Administration has granted approval for Tecartus ® for the treatment of adult patients with ...

Source: investingnews.com
Related Topics:
United StatesSanta MonicaUnited KingdomFoster CityBijal ShahChristi ShawMary Lynn CarverJacquie RossLee GreenbergerGilead SciencesAmerican Society Of Clinical OncologyLeukemia Lymphoma SocietyDrug AdministrationMoffitt Cancer CenterGilead Sciences IncUs Authorized Treatment CentersExchange CommissionGilead CompanyGilead Public AffairsEuropean UnionGilead Company NasdaqPatients Achieved Overall Complete RemissionHigh Unmet NeedFifty PercentAdult Patients Will Relapse